Our results are in line with the notion that MMR genes may predispose to a biologically different type of ovarian cancer than BRCA1/2 or in the general population, characterized by early stage disease at presentation and favorable prognosis [24]. This evidence concerns the gene MRC1 and ovarian carcinoma.